Gritstone Bio Current Ratio 2017-2024 | GRTSQ
Gritstone Bio current ratio from 2017 to 2024. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Gritstone Bio Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2024-06-30 |
$0.06B |
$0.02B |
2.54 |
| 2024-03-31 |
$0.05B |
$0.03B |
2.00 |
| 2023-12-31 |
$0.09B |
$0.03B |
3.20 |
| 2023-09-30 |
$0.09B |
$0.02B |
3.88 |
| 2023-06-30 |
$0.12B |
$0.02B |
5.54 |
| 2023-03-31 |
$0.16B |
$0.03B |
6.27 |
| 2022-12-31 |
$0.18B |
$0.04B |
5.26 |
| 2022-09-30 |
$0.15B |
$0.03B |
4.75 |
| 2022-06-30 |
$0.16B |
$0.03B |
4.99 |
| 2022-03-31 |
$0.19B |
$0.03B |
5.65 |
| 2021-12-31 |
$0.22B |
$0.04B |
5.52 |
| 2021-09-30 |
$0.22B |
$0.04B |
6.01 |
| 2021-06-30 |
$0.18B |
$0.02B |
8.25 |
| 2021-03-31 |
$0.20B |
$0.02B |
9.30 |
| 2020-12-31 |
$0.18B |
$0.03B |
6.50 |
| 2020-09-30 |
$0.07B |
$0.02B |
3.35 |
| 2020-06-30 |
$0.09B |
$0.02B |
4.93 |
| 2020-03-31 |
$0.11B |
$0.02B |
6.09 |
| 2019-12-31 |
$0.13B |
$0.02B |
6.73 |
| 2019-09-30 |
$0.16B |
$0.02B |
6.76 |
| 2019-06-30 |
$0.19B |
$0.02B |
10.22 |
| 2019-03-31 |
$0.14B |
$0.01B |
9.57 |
| 2018-12-31 |
$0.16B |
$0.02B |
10.43 |
| 2018-09-30 |
$0.08B |
$0.01B |
6.13 |
| 2018-06-30 |
$0.00B |
|
0.00 |
| 2018-03-31 |
$0.00B |
|
0.00 |
| 2017-12-31 |
$0.00B |
|
0.00 |
| 2017-09-30 |
$0.00B |
|
0.00 |
| 2016-12-31 |
$0.04B |
$0.00B |
15.39 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.016B |
|
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.
|
